Jim Cramer: How Iger and Benioff Let Twitter Get Away

Both are proud they dodged the Twitter bullet. But, in retrospect, was it really a bullet?

Fed Finally Gets It, Calling AT&T and Microsoft Delivers: Market Recon

A dividend hike and a big buyback authorization by Mr. Softee should produce value for shareholders.

I Have a Solution to Adobe's Growth Problem: DocuSign

The cloud stock's results weren't great, but were nothing close to the FedEx disaster.

VMware Shows New Strength, But Wait for a Dip or Retest to Buy

After a sprint higher in the IT company's shares in recent days, traders and investors might do well to wait for a temporary pullback to pick up the stock.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Palo Alto Networks Scoops Up Smaller Players, Smack Talks Competition

The cybersecurity name fired off some punches at the competition and picked up another bolt-on acquisition amid earnings.

Palo Alto Networks Surges, but Its Close Is More Important

Shares of the provider of network security platforms could bump into a resistance zone after a strong start.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.